PYC Therapeutics (PYC) Q1 2025 earnings summary

Executive summary

• Advancing a pipeline of genetic medicines for monogenic and rare diseases with severe unmet needs, targeting high-prevalence indications and aiming for human efficacy data in 2025 across multiple programs including RP11, ADOA, PKD/ADPKD, and PMS.

• Three clinical-stage assets (RP11, ADOA, PKD/ADPKD) are progressing rapidly, with significant clinical efficacy and safety data expected in the next 12–18 months.

• The company leverages patient-derived organoid models for preclinical validation, enhancing translational confidence and claims a 5x higher probability of success than industry average.

• Positioned for a transition to a commercial-stage, revenue-generating organization within a 48-month roadmap.

• Lead program for RP11 showed vision improvements in multiple patients after a single dose and completed repeat dosing in a Multiple Ascending Dose study; received Orphan Drug Designation from the US FDA.

Financial highlights

• Recently raised AUD 145 million via a rights issue/Entitlement Offer, increasing cash reserves to over $200 million and extending the cash runway into FY2027.

• Cash and cash equivalents at 30 September 2024 were $45.4 million, with an anticipated $17 million R&D tax rebate in the December quarter.

• Funding is secured for 24 months, supporting delivery of multiple value-creating milestones.

• Net cash used in operating activities for the quarter was $20.7 million, primarily for R&D and staff costs.

• No new financing facilities or borrowings reported during the quarter.

Outlook and guidance

• Multiple near-term clinical milestones expected, including key data readouts for RP11 and PKD/ADPKD in 2025 and ADOA in late 2025/early 2026.

• Clinical proof of concept data anticipated across three most advanced programs before end-2025; IND-enabling studies for PMS to begin in 2025.

• Transition to late-stage development and potential business development/licensing deals are anticipated as clinical data matures.

• ADPKD program benefits from an accelerated FDA approval pathway based on Total Kidney Volume outcomes.

• Focus remains on delivering excellent clinical efficacy data to drive value recognition and optionality for commercial transactions.